SNX-5422: Clinical Trials

8 completed, 3 terminated, 1 withdrawn. 11 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	11	Completed 8, Terminated 2, Withdrawn 1
Phase 2	2	Terminated 2

Follow SNX-5422: new trials by email Literature Review of SNX-5422 trials Research Report on SNX-5422

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL SNX-5422 plus ibrutinib - Cancer	Phase 1	Terminated	Esanex Inc.	5	2017-02-07	2019-02-22
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL SNX-5422 plus ibrutinib - Cancer	Phase 1	Withdrawn	Esanex Inc.		2017-02-02	2018-07-30
Study of SNX-5422 in TP53 Null Cancers SNX-5422 - Cancer	Phase 2	Terminated	Esanex Inc.	1	2016-03-01	2018-11-14
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors SNX-5422 - Cancer	Phase 1	Completed	Esanex Inc.	19	2014-02-01	2018-07-30
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies SNX-5422 - Cancer	Phase 1	Completed	Esanex Inc.	10	2014-02-01	2017-04-26
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors SNX-5422 - Cancer	Phase 1	Completed	Esanex Inc.	18	2013-11-01	2017-07-26
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers SNX-5422 - Cancer	Phase 1 / Phase 2	Terminated	Esanex Inc.	15	2013-04-01	2017-02-09
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma SNX-5422 - Cancer	Phase 1	Completed	Esanex Inc.	17	2013-03-01	2016-08-16
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies SNX-5422 - Cancer	Phase 1	Completed	Esanex Inc.	9	2012-05-01	2013-04-02
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas SNX-5422 - Lymphoma, Neoplasms	Phase 1	Completed	National Cancer Institute (NCI)	33	2008-03-07	2017-07-02
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies SNX-5422 - Hematologic Neoplasms	Phase 1	Completed	Esanex Inc.	25	2008-01-01	2012-05-17
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies SNX-5422 - Cancer	Phase 1	Completed	Esanex Inc.	44	2007-06-01	2012-05-28

Conditions studied

Neoplasms (11)  ·  Hematologic Neoplasms (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Adenocarcinoma of Lung (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Lymphoma (1)  ·  Neuroendocrine Tumors (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Esanex Inc. (11)  ·  National Cancer Institute (NCI) (1)

Countries

United States (11)